Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.
(2012) In European Journal of Haematology 88(4). p.329-335- Abstract
- Background: In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so. Objective: To describe and evaluate dosing and outcome of prophylactic treatment in a large cohort of adult people with severe haemophilia who have been using prophylaxis most of their lives. Methods: Eighty-one patients born between 1932 and1992 were divided into two groups (Group A started prophylaxis at the age of ≤ 3 years; Group B at three or more years of age) and evaluated retrospectively. Outcome was evaluated using the Hemophilia Joint Health Score (HJHS) and SF-36, a measure of quality of life. Results: The median number of joint bleeds per year was 0 in both study groups; however, the annual number... (More)
- Background: In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so. Objective: To describe and evaluate dosing and outcome of prophylactic treatment in a large cohort of adult people with severe haemophilia who have been using prophylaxis most of their lives. Methods: Eighty-one patients born between 1932 and1992 were divided into two groups (Group A started prophylaxis at the age of ≤ 3 years; Group B at three or more years of age) and evaluated retrospectively. Outcome was evaluated using the Hemophilia Joint Health Score (HJHS) and SF-36, a measure of quality of life. Results: The median number of joint bleeds per year was 0 in both study groups; however, the annual number of joint bleeds during the final three years of observation was higher in group B than group A (p< 0.006). Twenty-five of 30 patients in group A and 27/51 patients in group B had no joint bleeds in that period. Group A had significantly better joint outcomes than group B. Patients in group A experienced better physical and social health than those in group B. Conclusions: This follow-up has provided for the first time more extensive and detailed information regarding the practice of prophylactic treatment in a large cohort of adults with severe haemophilia. The present study confirms, that early start of prophylaxis and continuing throughout the lifespan has been successful in virtually eliminating joint bleeds, preserving a close to normal joint status, and keeping patients healthy and able to live normal lives. © 2012 John Wiley & Sons A/S. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/2336674
- author
- Khawaji, Mohammed LU ; Astermark, Jan LU and Berntorp, Erik LU
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- in
- European Journal of Haematology
- volume
- 88
- issue
- 4
- pages
- 329 - 335
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000301175300006
- pmid:22221195
- scopus:84858290843
- pmid:22221195
- ISSN
- 1600-0609
- DOI
- 10.1111/j.1600-0609.2012.01750.x
- language
- English
- LU publication?
- yes
- id
- 838aee0e-19c5-4ea2-8d36-981036c893d6 (old id 2336674)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/22221195?dopt=Abstract
- date added to LUP
- 2016-04-04 08:01:24
- date last changed
- 2022-02-20 21:13:05
@article{838aee0e-19c5-4ea2-8d36-981036c893d6, abstract = {{Background: In the 1950s, Sweden initiated prophylaxis as a lifelong treatment for haemophilia. It was the first country to do so. Objective: To describe and evaluate dosing and outcome of prophylactic treatment in a large cohort of adult people with severe haemophilia who have been using prophylaxis most of their lives. Methods: Eighty-one patients born between 1932 and1992 were divided into two groups (Group A started prophylaxis at the age of ≤ 3 years; Group B at three or more years of age) and evaluated retrospectively. Outcome was evaluated using the Hemophilia Joint Health Score (HJHS) and SF-36, a measure of quality of life. Results: The median number of joint bleeds per year was 0 in both study groups; however, the annual number of joint bleeds during the final three years of observation was higher in group B than group A (p< 0.006). Twenty-five of 30 patients in group A and 27/51 patients in group B had no joint bleeds in that period. Group A had significantly better joint outcomes than group B. Patients in group A experienced better physical and social health than those in group B. Conclusions: This follow-up has provided for the first time more extensive and detailed information regarding the practice of prophylactic treatment in a large cohort of adults with severe haemophilia. The present study confirms, that early start of prophylaxis and continuing throughout the lifespan has been successful in virtually eliminating joint bleeds, preserving a close to normal joint status, and keeping patients healthy and able to live normal lives. © 2012 John Wiley & Sons A/S.}}, author = {{Khawaji, Mohammed and Astermark, Jan and Berntorp, Erik}}, issn = {{1600-0609}}, language = {{eng}}, number = {{4}}, pages = {{329--335}}, publisher = {{Wiley-Blackwell}}, series = {{European Journal of Haematology}}, title = {{Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopaedic outcome and quality of life.}}, url = {{http://dx.doi.org/10.1111/j.1600-0609.2012.01750.x}}, doi = {{10.1111/j.1600-0609.2012.01750.x}}, volume = {{88}}, year = {{2012}}, }